VICTORIA: Cann Group Limited is launching a range of imported medicinal cannabis products for supply to approved Special Access Scheme (SAS) patients.

Cann has entered into a distribution agreement with Symbion Pty Ltd, which supplies healthcare services and products to more than 4000 retail pharmacies and 1300 hospitals throughout Australia.

Symbion will carry Cann’s full range of imported products, for supply to approved SAS patients in line with each state’s legislative requirements. Cann Group is also well advanced in its product manufacturing validation program with IDT Australia Ltd and expects to launch its first locally sourced and manufactured formulations in Q1 2020.

In addition, the Company has received its first shipment of a high THC oil formulation, which has been imported from strategic partner Aurora Cannabis in Canada. Permits are also in place for the import and supply of an additional five product presentations being supplied by Aurora.

Cann CEO, Peter Crock, said the Company is now entering its commercialisation phase, having successfully established a reliable cultivation and production capability. “We are now operating our existing Southern and Northern production facilities at full capacity, with in excess of 40harvests now completed, and we are advancing our product manufacturing capabilities with IDT Australia.”

Mr Crock said the distribution arrangement with Symbion will ensure that products can be supplied through approved pathways to patients throughout Australia who have been approved via the Special Access Scheme for medicinal cannabis treatment. In addition to finished product formulations, Cann is working with a network of Australian compounding pharmacies to develop the capacity to produce compounded products specifically formulated for individual patient needs.